Technology Bundle ID: TAB-2238

Identification of EGFR as A Receptor for AAV6 Transduction

Request More Info
Licensing Contact:
Primary Inventors: 
John Chiorini (NIDCR)
Co-Inventors: 
Melodie Weller (NIDCR), Michael Schmidt (NIDCR)
Application: 
Therapeutics
Development Status: 

Pre-clinical

Institute or Center: 
NIDCR

AAV vectors offer unique advantages in gene therapy applications. Studies have shown that these replication deficient parvovirus vectors can deliver DNA to specific tissues and confer long-term transgene expression in a variety of systems. Although many studies have looked at the tissue-specific expression elicited by each of the AAV serotypes, a true understanding of how AAV transduces these tissues is still unclear. Of the large AAV family, only a few receptors or co-receptors have been identified. The ability to better target transduction to specific tissues on the basis of the receptors that each serotype uses for entry is essential for selecting a serotype given the receptor expression in specific tissue, or to exploit altered receptor expression under disease conditions.

AAV6 has been reported to effectively transduce muscle, lung, brain, and multiple types of tumors, including gliomas and lung adenocarcinomas. By using a bioinformatics based screen approach, the NIH investigators discovered that the epidermal growth factor receptor (EGFR) is a co-receptor for AAV6 infection in mammalian cells, and is necessary for efficient vector internalization.

Applications:

Improved gene therapy applications

Patents

US Pat 8,808,684

Issued 2014-08-19
US Pat 9,439,979

Issued 2016-09-13

Publications

Weller ML, et al.
PMID 20473307

Updated

Mar 15, 2011

Data Source: 
tts